41 results about "Cancer Model" patented technology

Expression of TROP-2, an approximately 35 kDa transmembrane protein and a substrate of protein kinase C, has been linked to several cancers. TROP-2 is also known as GA733-1, epithelial glycoprotein 1(EGP-I) and tumor-associated calcium signal transducer-2. A monoclonal antibody against TROP-2 from the hybridoma AR47A6.4.2, deposited with the International Depository Authority of Canada (IDAC) asaccession number 141205-05, was previously shown to be a cancerous disease modifying antibody (CDMAB), preventing tumour growth and reducing tumour burden in several cancer models including prostate,pancreatic and breast cancer by cytotoxicity. The variable regions of this monoclonal antibody were also isolated, sequenced and complementarity determining regions (CDRs) determined. Now, a chimericantibody and humanized antibodies are generated that have similar TROP-2 binding activity as the parent 141205-05 monoclonal antibody. The monoclonal, chimeric and humanized antibodies can be conjugated to toxins, enzymes, radioactive compounds, cytokines, interferons, target or reporter moieties and hematogenous cells to treat cancer. These antibodies are also used in binding assays to determineTROP-2 expression on cells.

The invention relates to a rat liver cancer model with different liver matrix hardness backgrounds and a preparation method of the rat liver cancer model. The method for preparing the rat liver cancer model with different liver matrix backgrounds is characterized by specifically comprising the following steps of: after grouping the rats, injecting pure carbon tetrachloride to an abdominal region in a hypodermic manner; injecting a carbon tetrachloride-olive oil solution to the abdominal region in the hypodermic manner; detecting through a texture analyzer to form the rat model with different liver matrix hardness; taking liver cancer cells which are in-vitro cultured and grown well and injecting the liver cancer cells to the rat to form hypodermic liver cancer cells; in-situ planting the formed liver cancer tumor source to the rat model with different liver matrix hardness to obtain the rat liver cancer model with different liver matrix hardness backgrounds. The rat liver cancer model with different liver matrix hardness backgrounds can be used for well displaying liver cancer malignant pathological characteristics under the liver matrix hardness interference, simulating and reproducing pathological characteristics of clinical liver matrix hardening background liver cancer and solving the problems that an ideal experiment system, an animal model and the like are lacked in reaching the development of the liver cancer due to the liver matrix hardness changes.

The invention discloses a method for inducing a rat liver cancer model by injecting diethyl nitrosamine DEN in coordination with microcystin MC-LR into a rat body through intraperitoneal injection. Indexes such as liver weight to body weight ratio, liver appearance, liver histopathological slicing and GST-Pi (Glutathione S-transferase) protein expression level clearly show liver cell injury phase, liver cell hyperplasia-hepatocirrhosis phase and liver cell carcinomatous change process in a rat liver cancer occurring process, and find that the liver cancer model induced by the DEN in coordination with the microcystin MC-LR has a more obvious effect at the same time than that induced by DEN independently; the tumor formation time is shorter; and the model is an ideal model for researching occurrence of the liver cancer of a human body. The model has the characteristic of clearly showing each stage for occurrence of the liver cancer and contributing to research of a liver cancer occurrence process mechanism, detection of precancerous lesion and development of treatment medicaments.

The invention pertains to the field of biomedical technology, in particular to an orthotopic transplanted mouse liver cancer model which takes the research of the occurrence and development mechanisms of liver cancer and the development of anti-tumor drugs as the purposes, and the preparation method and the application thereof. The H22 cell strain of stable transfection EGFP is injected into the BALB / c mouse peritoneal cavity for amplification; the ascites is extracted from the H22 ascites cancer mouse peritoneal cavity, then cell separation is carried out and cell suspension is prepared; the mouse peritoneal cavity is opened, and the cell suspension is extracted by a micro-syringe to be injected into the mouse liver; a cotton bud with 75 percent alcohol is pressed on the needle hole till the surface of the liver does not bleed any more, and the needle hole is sealed by bonding agent; then the liver surface is washed by physiological saline, and layer separation is carried out and the peritoneal cavity is closed. The results show that the occurrence rate of mouse liver cancer is 100 percent and the natural remission rate is zero. The model is an ideal orthotopic liver cancer model which can be used in the research of the development and metastasis mechanisms of orthotopic liver cancer and can also be applicable to the development of anti-tumor drugs, the experimental treatment and diagnosis research of liver cancer.

Described are three-dimensional, engineered, biological cancer models, methods of producing the same, and methods of identifying a therapeutic agent for cancer in an individual utilizing the three-dimensional, engineered, biological cancer models.

The present invention relates to a non-human transgenic animal whose genome comprises a stably integrated transgenic nucleotide sequence encoding Lysine-specific Demethylase 1 (LSD1) operably linked to a promoter. The invention further concerns methods for generating the non-human animal and its use as a cancer model.

The invention relates to the field of medicines, relates to a method for establishing an animal model, and particularly relates to a method for establishing a human colon cancer transplanted carcinomamouse model. A preclinical tumor model is made through preprocessing mice with prostaglandin E2 and inoculating immunodeficient mice (Balb / c or NOD / SCID) with the in-vitro in-situ tumors of a patientagainst the defects of low establishing success rate and instability of existing colon cancer models. The invention provides a method for improving the success rate of a colon cancer PDX model, and especially provides the method for preparing the high-infiltration and high-metastasis stable human colon cancer transplanted carcinoma mouse model. The model has great values for preclinical evaluation, treatment and prognosis of the colon cancer.

Chimeric nonhuman mammals useful as inducible spontaneous cancer models are disclosed. The nonhuman mammals are obtained by introducing one or more genetically modified embryonic stem (ES) cells into an early stage embryo, and then implanting the manipulated embryo into a surrogate mother. The ES cells contain a recombinant oncogene, and also may contain a genetic mutation that deletes or inactivates a tumor suppressor gene. Models of different types of cancer are produced by introducing different combinations of genetic mutations into the ES cells that are introduced into the early stage embryo.

A process for preparing the visualized nasopharyngeal carcinoma model includes such steps as using green fluorescin gene for the transfection to the cells of nasopharyngeal carcinoma, using the proper needle to take the suspension of the living cancer cells, and in-situ inoculating to the nasopharyngeal position of mouse via mouth.

The invention relates to a method for using tasepi alkali to prepare the drug that restrains the growth of tumor vessel, which provides the method for building chicken blast allantois membrane non-small-cell lung cancer A549 tumor transplant cancer model. The invention uses said test model, ELISA, immunity protein label, and Real Time RCR test method to research the effects of tasepi alkali on the CAM vessel structure, the growth of tumor, the shape change and the fresh vessel distribution of tumor, the protein expression of VEGF and bFGF, the gene expressions of VEGF acceptors as flt-1 and flk-1 / KDR, the protein expressions of AKT and Erk1 / 2, and the phosphorylation level, to prove the function of tasepi alkali for restraining the growth of tumor vessel.

The present invention provides a rodent animal for studying the molecular mechanisms and physiological processes associated with uncontrolled cell growth, e.g. cancer, and with a modified FGFR4.

The invention provides methods of treating cancer using a Chd5 protein or an agonist thereof Also provided are diagnostics, screening methods of cancer therapeutics, and cancer models useful for studying cancer biology and drug screening.

Models useful in determining whether fibroblast growth factor 19 variant polypeptides having glucose-lowering activity and / or anti-obesity activity also exhibit favorable oncology-related profiles, and methods and uses associated therewith are provided. Also provided are methods of antagonizing the oncogenic activity of FGF19 in a subject and, in certain embodiments, methods of preventing or treating a disease, disorder or condition, such as a FGF19-dependent disease, disorder or condition, or a symptom thereof.

The invention discloses a building method of a mouse stomach cancer model. A four-week-old C57BL / 6 mouse is taken and placed in a tubular device, wherein movement of the mouse is restrained but the mouse can breathe freely in the tubular device; every stress period lasts for 25-30 days, and six to eight hours are needed every day; the interval between every two stress periods is 5-7 days, and two to three stress periods are needed; when stress is carried out, the mouse drinks water containing N-nitro compounds is provided for the mouse, medicine is fed for a week and is fed again after a week, normal drinking water is provided for the mouse at the medicine feeding intervals, and the mouse needs to be fed with medicine for five weeks; the mouse is bred for 35 weeks conventionally after the medicine feeding, and the mouse suffering the stomach cancer is obtained. According to prior literatures and reports, the stomach cancer formation rate obtained after MNU treatment is carried out on a C57BL / 6 mouse purely is about 30%; after the MNU treatment and the stress treatment are combined, the stomach cancer formation rate of the C57BL / 6 mouse increases to be 60%.

The invention provides a construction method of a mouse lung cancer model. The method includes the steps of: S1, taking C57BL / 6J wild-type mice of 6-8 weeks old, performing adaptation for 1-2 weeks, then putting the mice into a main cabinet of an inhalation exposure cabinet for benzopyrene exposure with the condition parameters of: 5d / week, 5-8h / day, a benzopyrene exposure concentration of 9-12microg / m<3>, and stopping feeding of the mice and allowing free drinking during the exposure; and S2, performing exposure for 23-28 weeks, thus obtaining the mouse lung cancer model. The invention belongs to the field of biotechnology. The method provided by the invention causes no artificial damage to the original structure of the lung, also does not cause infection or other interferences, conformsto the actual environmental exposure way of the human body, can better reflect the actual occurrence of lung cancer in the human body, and is beneficial to the development of lung cancer-related therapeutic drugs.

The invention relates to the field of medicaments, and in particular relates to polypeptide with functions of inhibiting Cyclin D protein expression and treating mantle cell lymphoma, the sequence is ETIRRAYPDAANLLNDRVL which is a brand-new sequence, the polypeptide is capable of in vitro inhibiting Mino cell proliferation and migration of the mantle cell lymphoma cell and treating the mantle cell lymphoma; the survival rate of mice is successfully increased in a body bearing cancer model experiment, and the potential new medicine development value is provided.

The invention belongs to the technical field of cancer model construction and discloses biological microemulsion micelle, bladder cancer cell suspension and a mouse air sac bladder cancer model construction method. The biological microemulsion micelle is prepared by steps: preparing PAMAM into 10% PAMAM solution by tumor growth promoting liquid; adding COOH-PEG-OH into the 10% PAMAM solution, and well mixing; mixing 5% aldehyde dextran with the above solution to obtain the biological microemulsion micelle. The cell suspension is obtained by mixing of digested log-phase bladder cancer cells and the biological microemulsion micelle. The bladder cancer cell suspension enables tumor clustering growth, prevents cancer cell migration and promotes tumor growth. The air sac bladder cancer model is characterized in that an air sac is adopted for replacement of a bladder and can be used for medicine perfusion, and high success rate and short tumor forming period are realized.

The invention relates to the technical field of teaching appliances and particularly relates to a breast mass inspection teaching mold. The mold includes a model body, wherein a bottom surface of themodel body is provided with an elliptical groove, a through hole and a first rectangular groove, a wall of the elliptical groove is equipped with a cancer model, a wall of the through hole is equippedwith a mass model, the cancer model, the mass model and a surface of lobular hyperplasia model are respectively equipped with a pressure sensor, and a lower surface of a rubber cover is equipped withan air bag. The mold is advantaged in that through setting the pressure sensors, when medical staff contact the pressure sensors, sound is generated by the mold body, problems that a breast mass inspection teaching mold has the poor teaching effect and is not conductive to improvement of work experience of the medical staff are solved, moreover, the air bag is set, so a display screen is protected, and a problem of damage to the display screen on the breast mass inspection teaching mold due to bump is solved.

The present invention is directed to fish whose genome has integrated therein an oncogenic nucleic acid operably linked to a promoter. Methods of making the fish and methods for their use are also provided. The fish may advantageously be utilized in methods of screening for drugs or agents that modulate oncogene-mediated neoplastic or hyperplastic transformation, or that modulate sensitivity to chemotherapy or radiation therapy. Immortal tumor cells lines, methods of making immortal tumor cell lines and methods of their use are also provided.

The invention relates to a rat liver cancer model with different liver matrix hardness backgrounds and a preparation method of the rat liver cancer model. The method for preparing the rat liver cancer model with different liver matrix backgrounds is characterized by specifically comprising the following steps of: after grouping the rats, injecting pure carbon tetrachloride to an abdominal region in a hypodermic manner; injecting a carbon tetrachloride-olive oil solution to the abdominal region in the hypodermic manner; detecting through a texture analyzer to form the rat model with different liver matrix hardness; taking liver cancer cells which are in-vitro cultured and grown well and injecting the liver cancer cells to the rat to form hypodermic liver cancer cells; in-situ planting the formed liver cancer tumor source to the rat model with different liver matrix hardness to obtain the rat liver cancer model with different liver matrix hardness backgrounds. The rat liver cancer model with different liver matrix hardness backgrounds can be used for well displaying liver cancer malignant pathological characteristics under the liver matrix hardness interference, simulating and reproducing pathological characteristics of clinical liver matrix hardening background liver cancer and solving the problems that an ideal experiment system, an animal model and the like are lacked in reaching the development of the liver cancer due to the liver matrix hardness changes.

The present invention provides a modified interleukin-7 and a use thereof. The modified IL-7 or an IL-7 fusion protein of the present invention comprising the same can be obtained in high yield, and biologically active in viral infection and cancer models. Therefore, they can be used for the prevention and treatment of various diseases.

Neuroblastoma is a tumor primarily affecting children. The current standard of care is not curative except in the rare case of a surgically-resectable lesion, although very high survival rates have been documented for low-risk neuroblastoma and moderate-risk neuroblastoma. Taurolidine was developed as an anti-infective, but it has been found to have surprising oncolytic activity in cell cultures and now in a rodent cancer model. This invention relates to the use of taurolidine for the treatment of neuroblastoma in juvenile mammals.

The invention provides methods of treating cancer using a Chd5 protein or an agonist thereof. Also provided are diagnostics, screening methods of cancer therapeutics, and cancer models useful for studying cancer biology and drug screening.

The invention provides a construction method of a mouse lung cancer model. The method includes the steps of: S1, taking C57BL / 6J wild-type mice of 6-8 weeks old, performing adaptation for 1-2 weeks, then putting the mice into a main cabinet of an inhalation exposure cabinet for benzopyrene exposure with the condition parameters of: 5d / week, 5-8h / day, a benzopyrene exposure concentration of 9-12microg / m<3>, and stopping feeding of the mice and allowing free drinking during the exposure; and S2, performing exposure for 23-28 weeks, thus obtaining the mouse lung cancer model. The invention belongs to the field of biotechnology. The method provided by the invention causes no artificial damage to the original structure of the lung, also does not cause infection or other interferences, conformsto the actual environmental exposure way of the human body, can better reflect the actual occurrence of lung cancer in the human body, and is beneficial to the development of lung cancer-related therapeutic drugs.

Chimeric nonhuman mammals useful as inducible spontaneous cancer models are disclosed. The nonhuman mammals are obtained by introducing one or more genetically modified embryonic stem (ES) cells into an early stage embryo, and then implanting the manipulated embryo into a surrogate mother. The ES cells contain a recombinant oncogene, and also may contain a genetic mutation that deletes or inactivates a tumor suppressor gene. Models of different types of cancer are produced by introducing different combinations of genetic mutations into the ES cells that are introduced into the early stage embryo.

Models useful in determining whether fibroblast growth factor 19 variant polypeptides having glucose-lowering activity and / or anti-obesity activity also exhibit favorable oncology-related profiles, and methods and uses associated therewith. Also provided are methods of antagonizing the oncogenic activity of FGF19 in a subject and, in certain embodiments, methods of preventing or treating a disease, disorder or condition, such as a FGF19-dependent disease, disorder or condition, or a symptom thereof.

Disclosed is a detection method for DNA repair-related genes which respond to low-level radiation, which includes the steps of (1) breeding AKR / J mice, as a thymus cancer model, and normal ICR mice in a low-dose radiation environment; (2) collecting thymuses from the AKR / J thymus cancer mouse model and the normal ICR mice which have been bred at the step (1); (3) analyzing genes in the thymuses collected at the step (2); (4) detecting, among the genes analyzed at the step (3), a DNA repair-associated gene expressed commonly or differentially in the AKR / J thymus cancer mouse model and the normal ICR mice; and (5) amplifying the gene detected at the step (4) and measuring the expression level thereof.

The invention provides an application of rhizopus niger extracellular polysaccharide to preparation of medicines for treating induced colon cancer. The rhizopus niger extracellular polysaccharide is obtained through further separation and purification on rhizopus nigricans of activating, fermentation culture, ethanol precipitation, deproteinization by a Sevage method, decolourization with macroporous resin and the like. The anti-tumor activity of the rhizopus niger extracellular polysaccharide is explored by establishing an AOM / DSS induced colon cancer mouse model and a DMH induced bandicoot colon cancer model through the rhizopus niger extracellular polysaccharide. The animal model experiment result indicates that the rhizopus niger extracellular polysaccharide can obviously restrain growth and development of tumors of an induced colon cancer mouse, and has significant prevention and treatment effects on the induced colon cancer. Besides, the rhizopus niger extracellular polysaccharide can increase the health state of mice, increase the survival rate of the mice and delay death.